Table IV.
Group | n | IL-2 (pg/L) | IL-4 (ng/L) | TNF-α (ng/L) | IFN-γ (ng/L) | ||||
---|---|---|---|---|---|---|---|---|---|
| |||||||||
Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | ||
Tα1 | 60 | 163.4±34.7 | 108.0±24.1 | 189.85±122.64 | 64.22±42.27 | 552.12±261.23 | 123.45±102.56 | 6.03±2.78 | 22.26±4.19 |
Control | 60 | 158.3±31.8 | 75.1±19.1 | 190.87±124.65 | 127.83±135.67 | 546.78±256.89 | 241.23±189.9 | 5.97±3.11 | 12.45±4.55 |
t | 0.702 | 6.771 | 0.045 | 3.438 | 0.112 | 4.190 | 0.110 | 12.182 | |
P | >0.05 | <0.001 | >0.05 | <0.001 | >0.05 | <0.001 | >0.05 | <0.001 |